Beigene Co. Ltd. has divulged antibody-drug conjugates (ADC) comprising HER3 (erbB3) targeting antibody linked to an effector molecule through a linker reported to be useful for the treatment of cancer, metabolic diseases, neurodegeneration and inflammation.
Novaccess Global Inc. has signed a letter of intent and formed a partnership with BCN Biosciences LLC to expand its immunotherapy platform. Utilizing BCN’s small-molecule drug BCN-057, Novaccess Global has begun the development of a fourth generation of its novel brain tumor immunotherapy TLR-AD-1, targeting glioblastoma.
Krystal Biotech Inc. has received FDA acceptance of its IND application for lead oncology drug candidate KB-707 for the treatment of locally advanced or metastatic solid tumor malignancies. KB-707 is a modified herpes simplex virus 1 (HSV-1) vector designed to deliver genes encoding both human IL-12 and IL-2 to the tumor microenvironment and promote systemic immune-mediated tumor clearance.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has identified immunostimulatory antibody-drug conjugates (ISAC) comprising immunomodulators (Toll-like receptor 7 [TLR7] and/or TLR8 agonists) bound to antibodies through cleavable or uncleavable linkers reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceuticals Co. Ltd. have disclosed antibody-drug conjugates (ADC) comprising human monoclonal antibodies targeting ROR1 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer.
Avencell Therapeutics Inc. has received approval from the EMA for its clinical trial application (CTA) for AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and other selected hematologic malignancies positive for CD123. A phase I study will be conducted in Germany.
Mabwell (Shanghai) Bioscience Co. has received approval from China's National Medical Products Administration (NMPA) for its clinical trial application for 7MW-3711 for advanced malignant solid tumors.
Mabwell (Shanghai) Bioscience Co. Ltd. has received clearance by China’s National Medical Products Administration (NMPA) for its clinical trial application for 9MW-2921 for advanced solid tumors.
Hangzhou Qihan Biotech Co. Ltd. has received clinical trial clearance from China’s National Medical Products Administration (NMPA) for QN-019a for CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
RSS
.png?height=488&t=1670008838&width=650 "Acute myeloid leukemia")
